The company

The pioneer and inventor of diagnostic devices that enable clinicians to non-invasively assess cardiovascular risk and diabetes risk.

Company

Established in 2003, Diagnoptics is the pioneer of cutting edge diagnostic devices that enable clinicians to non-invasively assess cardiovascular risk and diabetes risk. Its technological advance in detecting the autofluorescence of Advanced Glycation Endproducts (AGEs) in skin tissue has led to the invention of the AGE Reader – a state of art non-invasive medical device that allows the determination of the tissue accumulation of AGEs within 12 seconds.

AGEs are essential biomarkers of metabolic and glycemic stress and have been implicated as causative factors in the progression of a host of age-related diseases, such as chronic kidney disease, diabetes, atherosclerosis, and Alzheimer’s. The amount of AGEs in tissue serves as an important risk predictor for cardiovascular complications and for diabetes and its complications.

Mission

Diagnoptics’ mission is to provide clinicians with state of the art technology for the non-invasive assessment of tissue glycation and to improve the standard of care of cardiovascular risk assessment.

History

1995 – Dr. Smit and his co-workers made a coincidental finding of increased skin autofluorescence in many diabetes patients when they were performing fluorescein capillary leakage studies in diabetes.

1998 РThe first clinical studies in diabetes and renal failure were started with an advanced  AGE Reader prototype in the University Hospital Groningen, The Netherlands.

1999 – First patent for the AGE Reader and first scientific publication on the clinical use of the AGE Reader prototype in diabetic patients

2000 – Initiated the first large scale follow-up study in the Zwolle region

2003 – Dr. Smit and Dr. Graaff founded DiagnOptics in Groningen, the Netherlands

2004 – The first clinical study on the AGE Reader was published in Diabetologia

2005 – The AGE Reader SU was first demonstrated to future users (EASD, Athens 2005)

2006 – AGE Reader received market approval in Europe

2010 – Diagnoptics received ISO 13485 certification

2012 – First demonstration of the AGE Reader mu (EASD, Berlin 2012)

2013 – Product launch of the AGE Reader mu

2014 – Installed base > 2000 units

2015 – Deloitte Technology Fast50 sector winner Life Sciences

2015 – AGE Reader received market approval in Japan

2017 – Product launch of the AGE Scanner

2017 – AGE Reader received market approval in South Korea and several other countries

2018 – Product launch of the AGE Reader mu connect

2020 – Installed base > 5000 units

2022 – Initiated re-certification of the AGE Reader in Europe (MDR)

More Information
Request information

Would you like to learn more about our products? Request any information you wish to receive here.

Contact

Our contact details

Diagnoptics Technologies B.V.
Aarhusweg 4-9
9723 JJ Groningen
The Netherlands

Tel: +31 (0)50 589 0612
Fax: +31 (0)50 589 0613
E-mail: info@diagnoptics.com


Follow us on LinkedIn

About the company

More information about Diagnoptics.

Information for patients

Information on Diagnoptics' products and Advanced Glycation Endproducts.

Information for professionals

Information about Advanced Glycation Endproducts, the AGE measurement and clinical validation.